SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID (SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID).
Sodium picosulfate is a stimulant laxative that is converted by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane, which acts on the colonic mucosa to stimulate peristalsis and increase water and electrolyte secretion. Magnesium oxide and citric acid react in solution to form magnesium citrate, an osmotic laxative that draws water into the intestinal lumen, increasing stool volume and promoting bowel evacuation.
| Metabolism | Sodium picosulfate is hydrolyzed by colonic bacteria to its active metabolite; magnesium oxide and citric acid are not metabolized but form magnesium citrate in solution. |
| Excretion | Sodium picosulfate is primarily excreted in feces (biliary/fecal elimination) as active metabolite BHPM; <5% renal. Magnesium oxide is excreted renally as magnesium ions; absorbed magnesium is eliminated via kidneys. Anhydrous citric acid is metabolized in the Krebs cycle; minimal renal excretion. |
| Half-life | Sodium picosulfate active metabolite BHPM: terminal half-life approximately 7.4 hours; clinical duration of laxative effect extends beyond half-life due to colonic residence. |
| Protein binding | Sodium picosulfate active metabolite BHPM: ~95% bound to albumin. |
| Volume of Distribution | Sodium picosulfate active metabolite BHPM: Vd approximately 0.3 L/kg; low distribution consistent with high protein binding and limited tissue penetration. |
| Bioavailability | Sodium picosulfate is a prodrug; systemic bioavailability of active metabolite BHPM is low (approx 0.1%) after oral administration due to extensive first-pass hydrolysis to active form in colon. |
| Onset of Action | Oral: 6-12 hours for bowel preparation; effect typically begins within 1-3 hours after first dose. |
| Duration of Action | Oral: Duration of purgative effect 6-12 hours; complete bowel evacuation occurs within 24 hours. |
Adults: 10 mg sodium picosulfate, 3.5 g magnesium oxide, and 10.97 g anhydrous citric acid (reconstituted in water) as a single oral dose, followed by clear liquids. Two doses may be used in a split-dose regimen: first dose evening before procedure, second dose day of procedure at least 5 hours prior.
| Dosage form | FOR SOLUTION |
| Renal impairment | Contraindicated in GFR < 30 mL/min/1.73 m². For GFR 30-60 mL/min/1.73 m²: use with caution; monitor for fluid and electrolyte disturbances; consider alternative bowel preparation. No formal dose adjustment established. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution. |
| Pediatric use | Weight-based dosing (sodium picosulfate content): 10-20 kg: 5 mg; 20-30 kg: 7.5 mg; 30-40 kg: 10 mg; >40 kg: adult dose. Administer as a single or split dose with clear liquids. Not recommended for children < 10 kg. |
| Geriatric use | No specific dose adjustment required; same as adult dosing. Use with caution due to increased risk of dehydration, electrolyte abnormalities, and renal impairment. Ensure adequate hydration and monitor renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID (SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID).
| Breastfeeding | No data on excretion in human milk; M/P ratio unknown. Due to short half-life and minimal systemic absorption after oral administration, risk to nursing infant is likely low. However, caution is advised; monitor infant for diarrhea or electrolyte imbalance. |
| Teratogenic Risk | Insufficient human data; animal studies not available. The combination (bowel cleansing agent) is not intended for chronic use. Potential risks from electrolyte disturbances (e.g., hypermagnesemia) could affect fetal development, particularly if severe. Use only if clearly needed, and avoid in first trimester unless benefit outweighs unknown risks. |
■ FDA Black Box Warning
There is no FDA black box warning for this combination product.
| Serious Effects |
["Gastrointestinal obstruction or ileus","Bowel perforation","Toxic colitis or toxic megacolon","Gastric retention","Severe renal impairment (CrCl <30 mL/min)","Hypersensitivity to any component"]
| Precautions | ["Risk of fluid and electrolyte abnormalities (e.g., dehydration, hyponatremia, hypokalemia) especially in patients with renal impairment or those taking diuretics or ACE inhibitors","Serious fluid shifts may cause cardiac arrhythmias, seizures, or renal impairment","Use with caution in patients with a history of seizures, severe renal impairment (CrCl <30 mL/min), or electrolyte disturbances","Avoid in patients with gastrointestinal obstruction, perforation, or severe inflammatory bowel disease"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal electrolytes (sodium, potassium, magnesium, calcium) and renal function before and during use. Assess for signs of dehydration or fluid overload. Fetal heart rate monitoring if administered near term due to risk of maternal electrolyte shift. |
| Fertility Effects | No published studies on fertility. The drug is a short-term bowel cleansing agent; no anticipated long-term impact on fertility. However, severe electrolyte disturbances could transiently affect reproductive function. |